ID   TLR1_HUMAN              Reviewed;         786 AA.
AC   Q15399; D1CS39; D1CS41; O15452; Q32MK3; Q32MK4; Q9UG90;
DT   31-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2007, sequence version 3.
DT   22-FEB-2023, entry version 214.
DE   RecName: Full=Toll-like receptor 1;
DE   AltName: Full=Toll/interleukin-1 receptor-like protein;
DE            Short=TIL;
DE   AltName: CD_antigen=CD281;
DE   Flags: Precursor;
GN   Name=TLR1; Synonyms=KIAA0012;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS SER-248 AND ILE-602.
RC   TISSUE=Erythroleukemia;
RX   PubMed=9435236; DOI=10.1073/pnas.95.2.588;
RA   Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F.;
RT   "A family of human receptors structurally related to Drosophila Toll.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:588-593(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=18810425; DOI=10.1007/s00251-008-0332-0;
RA   Nakajima T., Ohtani H., Satta Y., Uno Y., Akari H., Ishida T., Kimura A.;
RT   "Natural selection in the TLR-related genes in the course of primate
RT   evolution.";
RL   Immunogenetics 60:727-735(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS THR-80 AND ILE-602.
RX   PubMed=19924287; DOI=10.1371/journal.pone.0007803;
RA   Georgel P., Macquin C., Bahram S.;
RT   "The heterogeneous allelic repertoire of human Toll-Like receptor (TLR)
RT   genes.";
RL   PLoS ONE 4:E7803-E7803(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-80.
RC   TISSUE=Bone marrow;
RX   PubMed=7584026; DOI=10.1093/dnares/1.1.27;
RA   Nomura N., Miyajima N., Sazuka T., Tanaka A., Kawarabayasi Y., Sato S.,
RA   Nagase T., Seki N., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. I. The
RT   coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of
RT   randomly sampled cDNA clones from human immature myeloid cell line KG-1.";
RL   DNA Res. 1:27-35(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS SER-248 AND ILE-602.
RC   TISSUE=Brain;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS SER-248 AND ILE-602.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 25-39.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TLR2 AND CD14.
RX   PubMed=16880211; DOI=10.1074/jbc.m602794200;
RA   Triantafilou M., Gamper F.G., Haston R.M., Mouratis M.A., Morath S.,
RA   Hartung T., Triantafilou K.;
RT   "Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers
RT   at the cell surface determines heterotypic associations with CD36 and
RT   intracellular targeting.";
RL   J. Biol. Chem. 281:31002-31011(2006).
RN   [9]
RP   INVOLVEMENT IN PROTECTION AGAINST LEPROSY.
RX   PubMed=17548585; DOI=10.4049/jimmunol.178.12.7520;
RA   Johnson C.M., Lyle E.A., Omueti K.O., Stepensky V.A., Yegin O., Alpsoy E.,
RA   Hamann L., Schumann R.R., Tapping R.I.;
RT   "Cutting edge: A common polymorphism impairs cell surface trafficking and
RT   functional responses of TLR1 but protects against leprosy.";
RL   J. Immunol. 178:7520-7524(2007).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-163.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [11]
RP   FUNCTION.
RC   TISSUE=T-cell;
RX   PubMed=21078852; DOI=10.1128/iai.00806-10;
RA   Lancioni C.L., Li Q., Thomas J.J., Ding X., Thiel B., Drage M.G.,
RA   Pecora N.D., Ziady A.G., Shank S., Harding C.V., Boom W.H., Rojas R.E.;
RT   "Mycobacterium tuberculosis lipoproteins directly regulate human memory
RT   CD4(+) T cell activation via Toll-like receptors 1 and 2.";
RL   Infect. Immun. 79:663-673(2011).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 625-785.
RX   PubMed=11081518; DOI=10.1038/35040600;
RA   Xu Y., Tao X., Shen B., Horng T., Medzhitov R., Manley J.L., Tong L.;
RT   "Structural basis for signal transduction by the Toll/interleukin-1
RT   receptor domains.";
RL   Nature 408:111-115(2000).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 25-476 IN COMPLEX WITH TLR2 AND
RP   BACTERIAL LIPOPEPTIDE ANALOG, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-51;
RP   ASN-163; ASN-330 AND ASN-429.
RX   PubMed=17889651; DOI=10.1016/j.cell.2007.09.008;
RA   Jin M.S., Kim S.E., Heo J.Y., Lee M.E., Kim H.M., Paik S.-G., Lee H.,
RA   Lee J.-O.;
RT   "Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a
RT   tri-acylated lipopeptide.";
RL   Cell 130:1071-1082(2007).
RN   [14]
RP   ASSOCIATION OF VARIANT SER-248 WITH SUSCEPTIBILITY TO LEPROSY.
RX   PubMed=19456232; DOI=10.1086/599121;
RA   Schuring R.P., Hamann L., Faber W.R., Pahan D., Richardus J.H.,
RA   Schumann R.R., Oskam L.;
RT   "Polymorphism N248S in the human Toll-like receptor 1 gene is related to
RT   leprosy and leprosy reactions.";
RL   J. Infect. Dis. 199:1816-1819(2009).
RN   [15]
RP   VARIANTS PRO-44; THR-75; THR-80; TYR-118; SER-248; LEU-305; LEU-315;
RP   ASN-352; VAL-460; ALA-542; CYS-554; GLY-587; ILE-602; ALA-651; ALA-674;
RP   PRO-720 AND LEU-733, AND CHARACTERIZATION OF VARIANTS LEU-315; CYS-554;
RP   ILE-602; ALA-651 AND PRO-720.
RX   PubMed=21618349; DOI=10.1002/humu.21486;
RA   Ben-Ali M., Corre B., Manry J., Barreiro L.B., Quach H., Boniotto M.,
RA   Pellegrini S., Quintana-Murci L.;
RT   "Functional characterization of naturally occurring genetic variants in the
RT   human TLR1-2-6 gene family.";
RL   Hum. Mutat. 32:643-652(2011).
CC   -!- FUNCTION: Participates in the innate immune response to microbial
CC       agents. Specifically recognizes diacylated and triacylated
CC       lipopeptides. Cooperates with TLR2 to mediate the innate immune
CC       response to bacterial lipoproteins or lipopeptides (PubMed:21078852).
CC       Forms the activation cluster TLR2:TLR1:CD14 in response to triacylated
CC       lipopeptides, this cluster triggers signaling from the cell surface and
CC       subsequently is targeted to the Golgi in a lipid-raft dependent pathway
CC       (PubMed:16880211). Acts via MYD88 and TRAF6, leading to NF-kappa-B
CC       activation, cytokine secretion and the inflammatory response.
CC       {ECO:0000269|PubMed:16880211, ECO:0000269|PubMed:21078852}.
CC   -!- SUBUNIT: Interacts (via extracellular domain) with TLR2. TLR2 seems to
CC       exist in heterodimers with either TLR1 or TLR6 before stimulation by
CC       the ligand. The heterodimers form bigger oligomers in response to their
CC       corresponding ligands as well as further heterotypic associations with
CC       other receptors such as CD14 and/or CD36 (PubMed:16880211,
CC       PubMed:17889651). The activation cluster TLR2:TLR1:CD14 forms in
CC       response to triacylated lipopeptides (PubMed:16880211). Binds MYD88
CC       (via TIR domain). Interacts with CNPY3 (By similarity).
CC       {ECO:0000250|UniProtKB:Q9EPQ1, ECO:0000269|PubMed:16880211,
CC       ECO:0000269|PubMed:17889651}.
CC   -!- INTERACTION:
CC       Q15399; Q15399: TLR1; NbExp=3; IntAct=EBI-9009517, EBI-9009517;
CC       Q15399; Q9BXR5: TLR10; NbExp=3; IntAct=EBI-9009517, EBI-16825459;
CC       Q15399; O60603: TLR2; NbExp=3; IntAct=EBI-9009517, EBI-973722;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16880211};
CC       Single-pass type I membrane protein {ECO:0000255}. Cytoplasmic vesicle,
CC       phagosome membrane {ECO:0000250|UniProtKB:Q9EPQ1}; Single-pass type I
CC       membrane protein {ECO:0000255}. Membrane raft
CC       {ECO:0000269|PubMed:16880211}. Golgi apparatus
CC       {ECO:0000269|PubMed:16880211}. Note=Does not reside in lipid rafts
CC       before stimulation but accumulates increasingly in the raft upon the
CC       presence of the microbial ligand. In response to triacylated
CC       lipoproteins, TLR2:TLR1 heterodimers are recruited in lipid rafts, this
CC       recruitment determine the intracellular targeting to the Golgi
CC       apparatus. {ECO:0000269|PubMed:16880211}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Highly expressed in spleen, ovary,
CC       peripheral blood leukocytes, thymus and small intestine.
CC   -!- POLYMORPHISM: Genetic variations in TLR1 may influence susceptibility
CC       to or protection against contracting leprosy and define the leprosy
CC       susceptibility locus 5 [MIM:613223]. Ser-602 is a common allele in
CC       Caucasians. It is associated with impaired cell surface expression and
CC       receptor function resulting in protection against leprosy.
CC   -!- SIMILARITY: Belongs to the Toll-like receptor family. {ECO:0000305}.
CC   -!- CAUTION: In some plant proteins and in human SARM1, the TIR domain has
CC       NAD(+) hydrolase (NADase) activity (By similarity). However, despite
CC       the presence of the catalytic Asp residue, the isolated TIR domain of
CC       human TLR4 lacks NADase activity (By similarity). Based on this, it is
CC       unlikely that Toll-like receptors have NADase activity.
CC       {ECO:0000250|UniProtKB:O00206, ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA02801.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U88540; AAC34137.1; -; mRNA.
DR   EMBL; AB445617; BAG55014.1; -; mRNA.
DR   EMBL; DQ012259; AAY85638.1; -; mRNA.
DR   EMBL; DQ012260; AAY85639.1; -; mRNA.
DR   EMBL; DQ012261; AAY85640.1; -; mRNA.
DR   EMBL; D13637; BAA02801.2; ALT_INIT; mRNA.
DR   EMBL; AL050262; CAB43364.1; -; mRNA.
DR   EMBL; BC109093; AAI09094.1; -; mRNA.
DR   EMBL; BC109094; AAI09095.1; -; mRNA.
DR   CCDS; CCDS33973.1; -.
DR   PIR; T08664; T08664.
DR   RefSeq; NP_003254.2; NM_003263.3.
DR   RefSeq; XP_005262719.1; XM_005262662.4.
DR   RefSeq; XP_011512044.1; XM_011513742.2.
DR   RefSeq; XP_011512045.1; XM_011513743.2.
DR   RefSeq; XP_011512046.1; XM_011513744.2.
DR   RefSeq; XP_011512047.1; XM_011513745.2.
DR   RefSeq; XP_016864060.1; XM_017008571.1.
DR   RefSeq; XP_016864061.1; XM_017008572.1.
DR   PDB; 1FYV; X-ray; 2.90 A; A=625-785.
DR   PDB; 2Z7X; X-ray; 2.10 A; B=25-475.
DR   PDB; 6NIH; X-ray; 2.30 A; A/B=1-475.
DR   PDB; 7NT7; NMR; -; A=625-786.
DR   PDB; 7NUW; X-ray; 1.90 A; A=625-785.
DR   PDB; 7NUX; X-ray; 2.47 A; A=625-785.
DR   PDBsum; 1FYV; -.
DR   PDBsum; 2Z7X; -.
DR   PDBsum; 6NIH; -.
DR   PDBsum; 7NT7; -.
DR   PDBsum; 7NUW; -.
DR   PDBsum; 7NUX; -.
DR   AlphaFoldDB; Q15399; -.
DR   SMR; Q15399; -.
DR   BioGRID; 112951; 22.
DR   ComplexPortal; CPX-2699; TLR1-TLR10 toll-like receptor complex.
DR   ComplexPortal; CPX-893; TLR1-TLR2 toll-like receptor complex.
DR   CORUM; Q15399; -.
DR   IntAct; Q15399; 6.
DR   STRING; 9606.ENSP00000354932; -.
DR   BindingDB; Q15399; -.
DR   ChEMBL; CHEMBL3714412; -.
DR   TCDB; 8.A.43.1.25; the neat-domain containing methaemoglobin heme sequestration (n-mhs) family.
DR   GlyCosmos; Q15399; 6 sites, No reported glycans.
DR   GlyGen; Q15399; 6 sites.
DR   iPTMnet; Q15399; -.
DR   PhosphoSitePlus; Q15399; -.
DR   BioMuta; TLR1; -.
DR   DMDM; 146291086; -.
DR   EPD; Q15399; -.
DR   jPOST; Q15399; -.
DR   MassIVE; Q15399; -.
DR   PaxDb; Q15399; -.
DR   PeptideAtlas; Q15399; -.
DR   ProteomicsDB; 60569; -.
DR   Antibodypedia; 10459; 691 antibodies from 43 providers.
DR   DNASU; 7096; -.
DR   Ensembl; ENST00000308979.7; ENSP00000354932.2; ENSG00000174125.8.
DR   Ensembl; ENST00000502213.6; ENSP00000421259.1; ENSG00000174125.8.
DR   GeneID; 7096; -.
DR   KEGG; hsa:7096; -.
DR   MANE-Select; ENST00000308979.7; ENSP00000354932.2; NM_003263.4; NP_003254.2.
DR   UCSC; uc003gtl.4; human.
DR   AGR; HGNC:11847; -.
DR   CTD; 7096; -.
DR   DisGeNET; 7096; -.
DR   GeneCards; TLR1; -.
DR   HGNC; HGNC:11847; TLR1.
DR   HPA; ENSG00000174125; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MalaCards; TLR1; -.
DR   MIM; 601194; gene.
DR   MIM; 613223; phenotype.
DR   neXtProt; NX_Q15399; -.
DR   OpenTargets; ENSG00000174125; -.
DR   PharmGKB; PA36549; -.
DR   VEuPathDB; HostDB:ENSG00000174125; -.
DR   eggNOG; KOG4641; Eukaryota.
DR   GeneTree; ENSGT00940000162884; -.
DR   HOGENOM; CLU_006000_3_0_1; -.
DR   InParanoid; Q15399; -.
DR   OMA; GTRMIHM; -.
DR   OrthoDB; 21383at2759; -.
DR   PhylomeDB; Q15399; -.
DR   TreeFam; TF351113; -.
DR   PathwayCommons; Q15399; -.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-1461957; Beta defensins.
DR   Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane.
DR   Reactome; R-HSA-168179; Toll Like Receptor TLR1:TLR2 Cascade.
DR   Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
DR   Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
DR   Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   SignaLink; Q15399; -.
DR   BioGRID-ORCS; 7096; 12 hits in 1153 CRISPR screens.
DR   EvolutionaryTrace; Q15399; -.
DR   GeneWiki; TLR_1; -.
DR   GenomeRNAi; 7096; -.
DR   Pharos; Q15399; Tbio.
DR   PRO; PR:Q15399; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q15399; protein.
DR   Bgee; ENSG00000174125; Expressed in monocyte and 144 other tissues.
DR   ExpressionAtlas; Q15399; baseline and differential.
DR   Genevisible; Q15399; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0043235; C:receptor complex; IPI:ComplexPortal.
DR   GO; GO:0035354; C:Toll-like receptor 1-Toll-like receptor 2 protein complex; IDA:MGI.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0071723; F:lipopeptide binding; IBA:GO_Central.
DR   GO; GO:0050135; F:NAD(P)+ nucleosidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0061809; F:NAD+ nucleotidase, cyclic ADP-ribose generating; IEA:UniProtKB-EC.
DR   GO; GO:0038023; F:signaling receptor activity; IBA:GO_Central.
DR   GO; GO:0035663; F:Toll-like receptor 2 binding; IPI:UniProtKB.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; NAS:UniProtKB.
DR   GO; GO:0071221; P:cellular response to bacterial lipopeptide; IBA:GO_Central.
DR   GO; GO:0071727; P:cellular response to triacyl bacterial lipopeptide; IDA:UniProtKB.
DR   GO; GO:0042495; P:detection of triacyl bacterial lipopeptide; IDA:MGI.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; NAS:ComplexPortal.
DR   GO; GO:0042116; P:macrophage activation; NAS:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; ISS:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IGI:ARUK-UCL.
DR   GO; GO:0034137; P:positive regulation of toll-like receptor 2 signaling pathway; IGI:ARUK-UCL.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; IDA:ComplexPortal.
DR   Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1.
DR   Gene3D; 3.40.50.10140; Toll/interleukin-1 receptor homology (TIR) domain; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR000157; TIR_dom.
DR   InterPro; IPR017241; Toll-like_receptor.
DR   InterPro; IPR035897; Toll_tir_struct_dom_sf.
DR   PANTHER; PTHR24365; TOLL-LIKE RECEPTOR; 1.
DR   PANTHER; PTHR24365:SF261; TOLL-LIKE RECEPTOR 1; 1.
DR   Pfam; PF13855; LRR_8; 2.
DR   Pfam; PF01463; LRRCT; 1.
DR   Pfam; PF01582; TIR; 1.
DR   PIRSF; PIRSF037595; Toll-like_receptor; 1.
DR   PRINTS; PR01537; INTRLKN1R1F.
DR   SMART; SM00364; LRR_BAC; 3.
DR   SMART; SM00369; LRR_TYP; 4.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00255; TIR; 1.
DR   SUPFAM; SSF52058; L domain-like; 1.
DR   SUPFAM; SSF52200; Toll/Interleukin receptor TIR domain; 1.
DR   PROSITE; PS51450; LRR; 10.
DR   PROSITE; PS50104; TIR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Cytoplasmic vesicle;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Golgi apparatus;
KW   Immunity; Inflammatory response; Innate immunity; Leucine-rich repeat;
KW   Membrane; NAD; Receptor; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           25..786
FT                   /note="Toll-like receptor 1"
FT                   /id="PRO_0000034705"
FT   TOPO_DOM        25..580
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        581..601
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        602..786
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          54..77
FT                   /note="LRR 1"
FT   REPEAT          78..101
FT                   /note="LRR 2"
FT   REPEAT          102..125
FT                   /note="LRR 3"
FT   REPEAT          126..150
FT                   /note="LRR 4"
FT   REPEAT          151..175
FT                   /note="LRR 5"
FT   REPEAT          176..199
FT                   /note="LRR 6"
FT   REPEAT          200..223
FT                   /note="LRR 7"
FT   REPEAT          224..250
FT                   /note="LRR 8"
FT   REPEAT          251..278
FT                   /note="LRR 9"
FT   REPEAT          279..308
FT                   /note="LRR 10"
FT   REPEAT          309..337
FT                   /note="LRR 11"
FT   REPEAT          338..361
FT                   /note="LRR 12"
FT   REPEAT          362..388
FT                   /note="LRR 13"
FT   REPEAT          389..414
FT                   /note="LRR 14"
FT   REPEAT          415..437
FT                   /note="LRR 15"
FT   REPEAT          438..457
FT                   /note="LRR 16"
FT   REPEAT          458..478
FT                   /note="LRR 17"
FT   REPEAT          479..500
FT                   /note="LRR 18"
FT   REPEAT          501..524
FT                   /note="LRR 19"
FT   DOMAIN          525..579
FT                   /note="LRRCT"
FT   DOMAIN          635..776
FT                   /note="TIR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00204"
FT   REGION          313..316
FT                   /note="Interaction with bacterial lipopeptide"
FT   CARBOHYD        51
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17889651"
FT   CARBOHYD        137
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        163
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17889651,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        330
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17889651"
FT   CARBOHYD        429
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17889651"
FT   CARBOHYD        578
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        110..132
FT                   /evidence="ECO:0000269|PubMed:17889651"
FT   DISULFID        223..230
FT                   /evidence="ECO:0000269|PubMed:17889651"
FT   DISULFID        343..368
FT                   /evidence="ECO:0000269|PubMed:17889651"
FT   DISULFID        419..442
FT                   /evidence="ECO:0000269|PubMed:17889651"
FT   VARIANT         44
FT                   /note="S -> P (in dbSNP:rs76600635)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_066340"
FT   VARIANT         75
FT                   /note="I -> T (in dbSNP:rs137853170)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_066341"
FT   VARIANT         80
FT                   /note="R -> T (in dbSNP:rs5743611)"
FT                   /evidence="ECO:0000269|PubMed:19924287,
FT                   ECO:0000269|PubMed:21618349, ECO:0000269|PubMed:7584026"
FT                   /id="VAR_031916"
FT   VARIANT         118
FT                   /note="H -> Y (in dbSNP:rs5743612)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_018474"
FT   VARIANT         248
FT                   /note="N -> S (may confer susceptibility to leprosy;
FT                   dbSNP:rs4833095)"
FT                   /evidence="ECO:0000269|PubMed:11230166,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:21618349,
FT                   ECO:0000269|PubMed:9435236"
FT                   /id="VAR_031917"
FT   VARIANT         305
FT                   /note="H -> L (in dbSNP:rs3923647)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_031918"
FT   VARIANT         315
FT                   /note="P -> L (severe impairment of activity;
FT                   dbSNP:rs5743613)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_031919"
FT   VARIANT         352
FT                   /note="H -> N (in dbSNP:rs76796448)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_066342"
FT   VARIANT         460
FT                   /note="I -> V (in dbSNP:rs137853171)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_066343"
FT   VARIANT         542
FT                   /note="V -> A (in dbSNP:rs137853172)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_066344"
FT   VARIANT         554
FT                   /note="Y -> C (severe impairment of activity;
FT                   dbSNP:rs137853173)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_066345"
FT   VARIANT         587
FT                   /note="V -> G (in dbSNP:rs5743617)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_031920"
FT   VARIANT         602
FT                   /note="S -> I (severe impairment of activity;
FT                   dbSNP:rs5743618)"
FT                   /evidence="ECO:0000269|PubMed:11230166,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:19924287,
FT                   ECO:0000269|PubMed:21618349, ECO:0000269|PubMed:9435236"
FT                   /id="VAR_031921"
FT   VARIANT         631
FT                   /note="L -> R (in dbSNP:rs5743619)"
FT                   /id="VAR_052358"
FT   VARIANT         651
FT                   /note="V -> A (severe impairment of activity;
FT                   dbSNP:rs137853174)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_066346"
FT   VARIANT         674
FT                   /note="V -> A"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_066347"
FT   VARIANT         720
FT                   /note="H -> P (severe impairment of activity;
FT                   dbSNP:rs113706342)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_066348"
FT   VARIANT         733
FT                   /note="P -> L (in dbSNP:rs5743621)"
FT                   /evidence="ECO:0000269|PubMed:21618349"
FT                   /id="VAR_052359"
FT   CONFLICT        182
FT                   /note="E -> G (in Ref. 5; CAB43364)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        228
FT                   /note="N -> S (in Ref. 5; CAB43364)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        276
FT                   /note="F -> S (in Ref. 5; CAB43364)"
FT                   /evidence="ECO:0000305"
FT   STRAND          28..30
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          48..51
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           62..65
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          73..75
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          83..85
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           86..89
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          97..99
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          107..109
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          117..120
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           133..137
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          143..150
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           153..159
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          164..171
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   TURN            173..178
FT                   /evidence="ECO:0007829|PDB:6NIH"
FT   HELIX           181..184
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          189..195
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          198..200
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          214..218
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          221..223
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   TURN            227..230
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           231..238
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           239..242
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          248..257
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           258..269
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          274..285
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          301..309
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           317..324
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          329..336
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          352..354
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   TURN            362..367
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          376..378
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           387..394
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          402..404
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           414..416
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          427..429
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           437..441
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          449..451
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           462..466
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          472..474
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   TURN            487..491
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           504..516
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   TURN            517..520
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   STRAND          521..523
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   TURN            529..531
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           536..538
FT                   /evidence="ECO:0007829|PDB:2Z7X"
FT   HELIX           628..630
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   STRAND          631..633
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   STRAND          637..642
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   HELIX           645..647
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   HELIX           648..653
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   HELIX           655..660
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   TURN            661..663
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   STRAND          666..668
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   TURN            669..671
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   HELIX           679..688
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   STRAND          690..698
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   HELIX           699..704
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   HELIX           706..713
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   STRAND          726..732
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   HELIX           736..738
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   HELIX           744..751
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   STRAND          755..757
FT                   /evidence="ECO:0007829|PDB:7NT7"
FT   HELIX           762..764
FT                   /evidence="ECO:0007829|PDB:7NUW"
FT   HELIX           765..777
FT                   /evidence="ECO:0007829|PDB:7NUW"
SQ   SEQUENCE   786 AA;  90291 MW;  1BFCCC5E42EA5242 CRC64;
     MTSIFHFAII FMLILQIRIQ LSEESEFLVD RSKNGLIHVP KDLSQKTTIL NISQNYISEL
     WTSDILSLSK LRILIISHNR IQYLDISVFK FNQELEYLDL SHNKLVKISC HPTVNLKHLD
     LSFNAFDALP ICKEFGNMSQ LKFLGLSTTH LEKSSVLPIA HLNISKVLLV LGETYGEKED
     PEGLQDFNTE SLHIVFPTNK EFHFILDVSV KTVANLELSN IKCVLEDNKC SYFLSILAKL
     QTNPKLSNLT LNNIETTWNS FIRILQLVWH TTVWYFSISN VKLQGQLDFR DFDYSGTSLK
     ALSIHQVVSD VFGFPQSYIY EIFSNMNIKN FTVSGTRMVH MLCPSKISPF LHLDFSNNLL
     TDTVFENCGH LTELETLILQ MNQLKELSKI AEMTTQMKSL QQLDISQNSV SYDEKKGDCS
     WTKSLLSLNM SSNILTDTIF RCLPPRIKVL DLHSNKIKSI PKQVVKLEAL QELNVAFNSL
     TDLPGCGSFS SLSVLIIDHN SVSHPSADFF QSCQKMRSIK AGDNPFQCTC ELGEFVKNID
     QVSSEVLEGW PDSYKCDYPE SYRGTLLKDF HMSELSCNIT LLIVTIVATM LVLAVTVTSL
     CSYLDLPWYL RMVCQWTQTR RRARNIPLEE LQRNLQFHAF ISYSGHDSFW VKNELLPNLE
     KEGMQICLHE RNFVPGKSIV ENIITCIEKS YKSIFVLSPN FVQSEWCHYE LYFAHHNLFH
     EGSNSLILIL LEPIPQYSIP SSYHKLKSLM ARRTYLEWPK EKSKRGLFWA NLRAAINIKL
     TEQAKK
//
